Vaccines and therapeutics for immunocompromised patients with COVID-19 / Shmuel Shoham, Carolina Batista, Yanis Ben Amor, Onder Ergonul, Mazen Hassanain, Peter Hotez, Gagandeep Kang, Jerome H. Kim, Bhavna Lall, Heidi J. Larson, Denise Naniche, Timothy Sheahan, Nathalie Strub-Wourgaft, Samba O. Sow, Annelies Wilder-Smith, Prashant Yadav, and Maria Elena Bottazzi, on behalf of the Lancet Commission on COVID-19 Vaccines and Therapeutics Task Force
The COVID-19 pandemic has disproportionately impacted immunocompromised patients. This diverse group is at increased risk for impaired vaccine responses, progression to severe disease, prolonged hospitalizations and deaths. At particular risk are people with deficiencies in lymphocyte number or function such as transplant recipients and those with hematologic malignancies. Such patients’ immune responses to vaccination and infection are frequently impaired leaving them more vulnerable to prolonged high viral loads and severe complications of COVID-19. Those in turn, have implications for disease progression and persistence, development of immune escape variants and transmission of infection. Data to guide vaccination and treatment approaches in immunocompromised people are generally lacking and extrapolated from other populations. The large clinical trials leading to authorisation and approval of SARS-CoV-2 vaccines and therapeutics included very few immunocompromised participants. While experience is accumulating, studies focused on the special circumstances of immunocompromised patients are needed to inform prevention and treatment approaches..
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
May 2023 2023 |
|---|---|
| Erschienen: |
May 2023 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:59 |
|---|---|
| Enthalten in: |
EClinicalMedicine - 59(2023) vom: Mai, Artikel-ID 101965, Seite 1-7 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Shoham, Shmuel [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
COVID-19 |
|---|
| Anmerkungen: |
Online verfügbar: 12. April 2023 Gesehen am 31.08.2023 |
|---|
| Umfang: |
7 |
|---|
| doi: |
10.1016/j.eclinm.2023.101965 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
1858441285 |
|---|
| LEADER | 01000caa a2200265 4500 | ||
|---|---|---|---|
| 001 | 1858441285 | ||
| 003 | DE-627 | ||
| 005 | 20240307055006.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 230831s2023 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1016/j.eclinm.2023.101965 |2 doi | |
| 035 | |a (DE-627)1858441285 | ||
| 035 | |a (DE-599)KXP1858441285 | ||
| 035 | |a (OCoLC)1425212472 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rda | ||
| 041 | |a eng | ||
| 100 | 1 | |a Shoham, Shmuel |e verfasserin |0 (DE-588)1300576537 |0 (DE-627)1858441560 |4 aut | |
| 245 | 1 | 0 | |a Vaccines and therapeutics for immunocompromised patients with COVID-19 |c Shmuel Shoham, Carolina Batista, Yanis Ben Amor, Onder Ergonul, Mazen Hassanain, Peter Hotez, Gagandeep Kang, Jerome H. Kim, Bhavna Lall, Heidi J. Larson, Denise Naniche, Timothy Sheahan, Nathalie Strub-Wourgaft, Samba O. Sow, Annelies Wilder-Smith, Prashant Yadav, and Maria Elena Bottazzi, on behalf of the Lancet Commission on COVID-19 Vaccines and Therapeutics Task Force |
| 264 | 1 | |c May 2023 | |
| 300 | |a 7 | ||
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Online verfügbar: 12. April 2023 | ||
| 500 | |a Gesehen am 31.08.2023 | ||
| 520 | |a The COVID-19 pandemic has disproportionately impacted immunocompromised patients. This diverse group is at increased risk for impaired vaccine responses, progression to severe disease, prolonged hospitalizations and deaths. At particular risk are people with deficiencies in lymphocyte number or function such as transplant recipients and those with hematologic malignancies. Such patients’ immune responses to vaccination and infection are frequently impaired leaving them more vulnerable to prolonged high viral loads and severe complications of COVID-19. Those in turn, have implications for disease progression and persistence, development of immune escape variants and transmission of infection. Data to guide vaccination and treatment approaches in immunocompromised people are generally lacking and extrapolated from other populations. The large clinical trials leading to authorisation and approval of SARS-CoV-2 vaccines and therapeutics included very few immunocompromised participants. While experience is accumulating, studies focused on the special circumstances of immunocompromised patients are needed to inform prevention and treatment approaches. | ||
| 650 | 4 | |a COVID-19 | |
| 650 | 4 | |a Immunocompromised | |
| 650 | 4 | |a Malignancy | |
| 650 | 4 | |a SARS-CoV-2 | |
| 650 | 4 | |a Transplantation | |
| 700 | 1 | |a Batista, Carolina |e verfasserin |4 aut | |
| 700 | 1 | |a Ben Amor, Yanis |e verfasserin |4 aut | |
| 700 | 1 | |a Ergonul, Onder |e verfasserin |4 aut | |
| 700 | 1 | |a Hassanain, Mazen |e verfasserin |4 aut | |
| 700 | 1 | |a Hotez, Peter |e verfasserin |4 aut | |
| 700 | 1 | |a Kang, Gagandeep |e verfasserin |4 aut | |
| 700 | 1 | |a Kim, Jerome H. |e verfasserin |4 aut | |
| 700 | 1 | |a Lall, Bhavna |e verfasserin |4 aut | |
| 700 | 1 | |a Larson, Heidi J. |e verfasserin |4 aut | |
| 700 | 1 | |a Naniche, Denise |e verfasserin |4 aut | |
| 700 | 1 | |a Sheahan, Timothy |e verfasserin |4 aut | |
| 700 | 1 | |a Strub-Wourgaft, Nathalie |e verfasserin |4 aut | |
| 700 | 1 | |a Sow, Samba O. |e verfasserin |4 aut | |
| 700 | 1 | |a Wilder-Smith, Annelies |e verfasserin |0 (DE-588)1064971458 |0 (DE-627)815377339 |0 (DE-576)186940998 |4 aut | |
| 700 | 1 | |a Yadav, Prashant |e verfasserin |4 aut | |
| 700 | 1 | |a Bottazzi, Maria Elena |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t EClinicalMedicine |d Amsterdam : Elsevier, 2018 |g 59(2023) vom: Mai, Artikel-ID 101965, Seite 1-7 |h Online-Ressource |w (DE-627)1035271834 |w (DE-600)2946413-4 |w (DE-576)512181683 |x 2589-5370 |7 nnns |
| 773 | 1 | 8 | |g volume:59 |g year:2023 |g month:05 |g elocationid:101965 |g pages:1-7 |g extent:7 |
| 856 | 4 | 0 | |u https://doi.org/10.1016/j.eclinm.2023.101965 |x Verlag |x Resolving-System |z kostenfrei |3 Volltext |
| 856 | 4 | 0 | |u https://www.sciencedirect.com/science/article/pii/S2589537023001426 |x Verlag |z kostenfrei |3 Volltext |
| 912 | |a GBV_USEFLAG_U | ||
| 912 | |a GBV_ILN_2013 | ||
| 912 | |a ISIL_DE-16-250 | ||
| 912 | |a SYSFLAG_1 | ||
| 912 | |a GBV_KXP | ||
| 912 | |a GBV_ILN_20 | ||
| 912 | |a GBV_ILN_22 | ||
| 912 | |a GBV_ILN_23 | ||
| 912 | |a GBV_ILN_24 | ||
| 912 | |a GBV_ILN_31 | ||
| 912 | |a GBV_ILN_39 | ||
| 912 | |a GBV_ILN_40 | ||
| 912 | |a GBV_ILN_60 | ||
| 912 | |a GBV_ILN_62 | ||
| 912 | |a GBV_ILN_63 | ||
| 912 | |a GBV_ILN_65 | ||
| 912 | |a GBV_ILN_69 | ||
| 912 | |a GBV_ILN_73 | ||
| 912 | |a GBV_ILN_74 | ||
| 912 | |a GBV_ILN_95 | ||
| 912 | |a GBV_ILN_105 | ||
| 912 | |a GBV_ILN_110 | ||
| 912 | |a GBV_ILN_151 | ||
| 912 | |a GBV_ILN_161 | ||
| 912 | |a GBV_ILN_170 | ||
| 912 | |a GBV_ILN_206 | ||
| 912 | |a GBV_ILN_213 | ||
| 912 | |a GBV_ILN_230 | ||
| 912 | |a GBV_ILN_285 | ||
| 912 | |a GBV_ILN_293 | ||
| 912 | |a GBV_ILN_602 | ||
| 912 | |a GBV_ILN_2014 | ||
| 912 | |a GBV_ILN_2446 | ||
| 912 | |a GBV_ILN_4012 | ||
| 912 | |a GBV_ILN_4037 | ||
| 912 | |a GBV_ILN_4112 | ||
| 912 | |a GBV_ILN_4125 | ||
| 912 | |a GBV_ILN_4126 | ||
| 912 | |a GBV_ILN_4249 | ||
| 912 | |a GBV_ILN_4305 | ||
| 912 | |a GBV_ILN_4306 | ||
| 912 | |a GBV_ILN_4307 | ||
| 912 | |a GBV_ILN_4313 | ||
| 912 | |a GBV_ILN_4322 | ||
| 912 | |a GBV_ILN_4323 | ||
| 912 | |a GBV_ILN_4324 | ||
| 912 | |a GBV_ILN_4325 | ||
| 912 | |a GBV_ILN_4338 | ||
| 912 | |a GBV_ILN_4367 | ||
| 912 | |a GBV_ILN_4700 | ||
| 912 | |a GBV_ILN_2403 | ||
| 912 | |a GBV_ILN_2403 | ||
| 912 | |a ISIL_DE-LFER | ||
| 951 | |a AR | ||
| 952 | |d 59 |j 2023 |c 5 |i 101965 |h 1-7 |g 7 | ||
| 980 | |2 2013 |1 01 |x DE-16-250 |b 4371443990 |c 00 |f --%%-- |d --%%-- |e --%%-- |j --%%-- |y l01 |z 31-08-23 | ||
| 980 | |2 2403 |1 01 |x DE-LFER |b 4376996645 |c 00 |f --%%-- |d --%%-- |e n |j --%%-- |y l01 |z 16-09-23 | ||
| 981 | |2 2403 |1 01 |x DE-LFER |r https://doi.org/10.1016/j.eclinm.2023.101965 | ||
| 981 | |2 2403 |1 01 |x DE-LFER |r https://www.sciencedirect.com/science/article/pii/S2589537023001426 | ||
| 982 | |2 2013 |1 01 |x DE-16-250 |8 00 |s s |a hd2023 | ||
| 982 | |2 2013 |1 01 |x DE-16-250 |8 01 |s s |0 (DE-627)1410508463 |a wissenschaftlicher Artikel (Zeitschrift) | ||
| 982 | |2 2013 |1 01 |x DE-16-250 |8 02 |s s |a per_17 | ||
| 982 | |2 2013 |1 01 |x DE-16-250 |8 03 |s s |a s_7 | ||
| 982 | |2 2013 |1 01 |x DE-16-250 |8 04 |s p |0 (DE-627)1494660172 |a Wilder-Smith, Annelies | ||
| 982 | |2 2013 |1 01 |x DE-16-250 |8 04 |s k |0 (DE-627)1493871218 |a Institut für Public Health (IPH) | ||
| 982 | |2 2013 |1 01 |x DE-16-250 |8 04 |s s |0 (DE-627)1410501914 |a Verfasser | ||
| 982 | |2 2013 |1 01 |x DE-16-250 |8 04 |s s |a pos_15 | ||